Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 2.83
4.04 %
$ 7.04 M
Market Cap
-0.5
P/E
1. INTRINSIC VALUE
Balance Sheet
Mangoceuticals, Inc.
| Current Assets | 818 K |
| Cash & Short-Term Investments | 739 K |
| Receivables | 0 |
| Other Current Assets | 79.5 K |
| Non-Current Assets | 232 K |
| Long-Term Investments | 0 |
| PP&E | 215 K |
| Other Non-Current Assets | 16.9 K |
| Current Liabilities | 211 K |
| Accounts Payable | 141 K |
| Short-Term Debt | 63.7 K |
| Other Current Liabilities | 6.6 K |
| Non-Current Liabilities | 65 K |
| Long-Term Debt | 65 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Mangoceuticals, Inc.
| Revenue | 731 K |
| Cost Of Revenue | 300 K |
| Gross Profit | 432 K |
| Operating Expenses | 9.65 M |
| Operating Income | -9.22 M |
| Other Expenses | -6.47 K |
| Net Income | -9.21 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mangoceuticals, Inc.
| Net Income | -9.21 M |
| Depreciation & Amortization | 24.9 K |
| Capital Expenditures | -3.52 K |
| Stock-Based Compensation | 624 K |
| Change in Working Capital | 41.5 K |
| Others | 1.46 M |
| Free Cash Flow | -7 M |
Wall Street Analysts Price Targets
Mangoceuticals, Inc.
MGRX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
MGRX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Mangoceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
39.8 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
7 months ago
Jun 25, 2024
|
Sell 5.14 K
USD
|
Hamilton Alex P.
Director
|
- 16574
|
0.31 USD |
|
7 months ago
Jun 26, 2024
|
Sell 34.7 K
USD
|
Hamilton Alex P.
Director
|
- 108426
|
0.32 USD |
|
1 year ago
Apr 10, 2023
|
Bought
275 K USD
|
Cohen Jacob D.
Chief Executive Officer
|
+ 275000
|
1 USD |
7. News
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness.
globenewswire.com
- 1 month ago
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly's claims and intends to vigorously defend itself in this matter.
globenewswire.com
- 3 months ago
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas. Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT.
newsfilecorp.com
- 3 months ago
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-15 (the “Reverse Stock Split”). The Reverse Stock Split will become effective on October 16, 2024 at 12:01 a.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on October 16, 2024. In connection with the Reverse Stock Split, every fifteen shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock, “MGRX”, in connection with the reverse split.
globenewswire.com
- 3 months ago
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
globenewswire.com
- 3 months ago
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category
globenewswire.com
- 4 months ago
MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues.
globenewswire.com
- 5 months ago
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinforcing its commitment to innovation and superior patient care.
globenewswire.com
- 5 months ago
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing Exhibit DALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in developing, marketing, and selling a variety of men's health and wellness products, is pleased to announce the receipt of its first Request for Proposal (RFP) from its distributor, the International Society of Frontier Life Sciences and Technology (ISFLST). This RFP focuses on the formulation, production, and packaging of a new male enhancement non-prescription product, intended to be introduced and sold in the Chinese market as a natural solution for men's health.
accesswire.com
- 5 months ago
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a leader in men's health and wellness products including erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce the initiation of efficacy studies on its patented respiratory illness prevention technology in collaboration with Vipragen Biosciences and IntraMont Technologies, Inc. Notably, these trials have been pre-funded, ensuring that the Company does not need to raise any additional capital for the completion of these studies, which are anticipated to be concluded in the earlier part of the 3rd quarter.
globenewswire.com
- 6 months ago
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that its CEO, Jacob Cohen, was recently featured on Benzinga All-Access.
globenewswire.com
- 6 months ago
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce obtaining DEA authorization for the company's groundbreaking HIPAA-compliant operating system through Surescripts . This significant milestone positions MangoRx at the forefront of the direct-to-consumer (DTC) telemedicine market.
globenewswire.com
- 6 months ago
8. Profile
Summary
Mangoceuticals, Inc. MGRX
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 7.04 M
Dividend Yield
0.00%
Description
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Contact
15110 North Dallas Parkway, Dallas, TX, 75248
https://www.mangorx.com
IPO
Date
March 21, 2023
Employees
3
Officers
Mr. Eugene M. Johnston
Chief Financial Officer
Ms. Amanda Elizabeth Hammer
Chief Operating Officer
Mr. Jacob D. Cohen
Co-Founder, Chief Executive Officer & Chairman